ES2386029T3 - Formas sólidas de un antagonista de receptor de quimiocina y procedimientos de uso del mismo - Google Patents

Formas sólidas de un antagonista de receptor de quimiocina y procedimientos de uso del mismo Download PDF

Info

Publication number
ES2386029T3
ES2386029T3 ES05854594T ES05854594T ES2386029T3 ES 2386029 T3 ES2386029 T3 ES 2386029T3 ES 05854594 T ES05854594 T ES 05854594T ES 05854594 T ES05854594 T ES 05854594T ES 2386029 T3 ES2386029 T3 ES 2386029T3
Authority
ES
Spain
Prior art keywords
citrate salt
weight
crystalline
propyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05854594T
Other languages
English (en)
Spanish (es)
Inventor
Carole Neves
Aurelia Chevalier
Pascal Billot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2386029T3 publication Critical patent/ES2386029T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES05854594T 2004-12-17 2005-12-19 Formas sólidas de un antagonista de receptor de quimiocina y procedimientos de uso del mismo Expired - Lifetime ES2386029T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63721304P 2004-12-17 2004-12-17
US637213P 2004-12-17
PCT/US2005/045915 WO2006066200A2 (en) 2004-12-17 2005-12-19 Solid forms of a chemokine receptor antagonist and methods of use thereof

Publications (1)

Publication Number Publication Date
ES2386029T3 true ES2386029T3 (es) 2012-08-07

Family

ID=36588631

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05854594T Expired - Lifetime ES2386029T3 (es) 2004-12-17 2005-12-19 Formas sólidas de un antagonista de receptor de quimiocina y procedimientos de uso del mismo

Country Status (9)

Country Link
US (2) US7960549B2 (cg-RX-API-DMAC10.html)
EP (1) EP1841429B1 (cg-RX-API-DMAC10.html)
JP (3) JP5308030B2 (cg-RX-API-DMAC10.html)
CN (1) CN101119725B (cg-RX-API-DMAC10.html)
AT (1) ATE553761T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005316340B2 (cg-RX-API-DMAC10.html)
CA (1) CA2590157C (cg-RX-API-DMAC10.html)
ES (1) ES2386029T3 (cg-RX-API-DMAC10.html)
WO (1) WO2006066200A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020390992A1 (en) * 2019-11-29 2022-06-09 Sunshine Lake Pharma Co., Ltd. Crystalline form of nitrogen-containing tricyclic compound and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509346B2 (en) * 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1999037619A1 (en) 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
DK1049700T3 (da) 1998-01-21 2006-02-20 Millennium Pharm Inc Kemokinreceptorantagonister og fremgangsmåder til anvendelse deraf
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
HU228314B1 (hu) 1998-09-04 2013-03-28 Millennium Pharmaceuticals Kemokin receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
EP1109815A1 (en) 1998-09-04 2001-06-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6503926B2 (en) 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU6503900A (en) 1999-07-28 2001-02-19 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor

Also Published As

Publication number Publication date
US20120065223A1 (en) 2012-03-15
EP1841429B1 (en) 2012-04-18
WO2006066200A3 (en) 2007-01-25
CN101119725B (zh) 2013-04-17
JP5308030B2 (ja) 2013-10-09
US7960549B2 (en) 2011-06-14
AU2005316340B2 (en) 2012-01-19
HK1109350A1 (en) 2008-06-06
AU2005316340A1 (en) 2006-06-22
JP2015057445A (ja) 2015-03-26
CA2590157C (en) 2013-11-05
ATE553761T1 (de) 2012-05-15
JP2008524253A (ja) 2008-07-10
CN101119725A (zh) 2008-02-06
WO2006066200A2 (en) 2006-06-22
JP2012211197A (ja) 2012-11-01
US20070010545A1 (en) 2007-01-11
US8481737B2 (en) 2013-07-09
EP1841429A2 (en) 2007-10-10
CA2590157A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
US12473286B2 (en) Salts of an FGFR inhibitor
TWI823169B (zh) 黑皮質素受體促效劑化合物的晶形ⅲ及其製備方法
TWI834791B (zh) 吡咯啶化合物的結晶
JP2022530441A (ja) ７ｈ－ピロロ［２，３－ｄ］ピリミジンｊａｋ－阻害剤
JP2023548161A (ja) メラノコルチン受容体アゴニスト化合物の結晶形ｉｖおよびその製造方法
CA2373607A1 (en) Cyclic amine derivatives and their uses
JP2023548163A (ja) メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法
BR112013007113B1 (pt) Sal de oxalato do conjugado naloxol-polietilenoglicol cristalino
JP2013540810A (ja) １−｛（２Ｓ）−２−アミノ−４−［２，４−ビス（トリフルオロメチル）−５，８−ジヒドロピリド［３，４−ｄ］ピリミジン−７（６Ｈ）−イル］−４−オキソブチル｝−５，５−ジフルオロピペリジン−２−オン酒石酸塩の水和物
JP2026512051A (ja) ベンズイミダゾール誘導体の塩
ES2412357T3 (es) Cocristales de metronidazol
US20250026773A1 (en) Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof
AU2023247631B2 (en) P2x3 inhibitor compound, salt thereof, polymorph thereof and use thereof
US20120165260A2 (en) Crystalline ezatiostat hydrochloride ansolvate
ES2553584T3 (es) Polimorfos de Febuxostat
KR20210008829A (ko) 디히드로피리미딘 화합물의 고체 형태 및 이의 제조 방법 및 이의 용도
JP2024518055A (ja) メラノコルチン受容体アゴニスト化合物の結晶形ｖおよびその製造方法
CN114853762B (zh) 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
US8481737B2 (en) Solid forms of a chemokine receptor antagonist and methods of use thereof
HK1109350B (en) Solid forms of a chemokine receptor antagonist and methods of use thereof
KR20070105354A (ko) 오카페리돈 염 및 이를 함유한 약제학적 조성물
WO2023179758A1 (zh) 稠合三并环衍生物或其可药用盐的结晶
HK40036995A (en) Crystals of glycyrrhizic acid derivatives, crystalline compositions, pharmaceutical compositions and uses thereof
JPWO2013058361A1 (ja) アンドロゲン受容体拮抗化合物の結晶